Literature DB >> 11785282

Identifying and slowing progressive chronic renal failure.

B Curtis1, B J Barrett, A Levin.   

Abstract

OBJECTIVE: To help inform primary care physicians about how to identify and slow progressive chronic renal failure. QUALITY OF EVIDENCE: The National Library of Medicine (1996 to 2000) was searched using PubMed with search terms pertinent to studies on identification, course, and management of chronic renal failure. References in retrieved papers and older literature known to the authors supplemented the searches. In general, sufficient high-quality studies, systematic reviews, or guidelines based on such evidence were available to support our main points. MAIN MESSAGE: End-stage renal disease (ESRD) poses a large and growing morbidity, mortality, and financial burden. Almost all patients reach ESRD as a result of chronic progressive conditions, particularly diabetic nephropathy, hypertensive-vascular renal disease, and glomerular disorders. Patients at risk merit regular renal assessment with serum creatinine tests and urinalysis. Persistent high blood pressure and heavy proteinuria are the strongest predictors of progression of chronic renal failure. Patients with renal disease should be examined and treated for vascular disease and vice versa. Blood pressure lowering, ACE inhibition, and avoidance of further renal insults (such as use of nephrotoxins) can slow the decline of renal function. Restricting dietary protein has a weak effect on slowing renal failure and is not easy to apply in primary care. Timely involvement of specialized nephrology teams is important.
CONCLUSION: Family physicians play an important role in recognizing patients with potential for renal failure, in demonstrating progressive chronic renal failure, and in initiating therapy early to improve outcomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11785282      PMCID: PMC2018474     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  61 in total

1.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.

Authors:  I Giatras; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  1997-09-01       Impact factor: 25.391

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.

Authors:  J M Lazarus; J J Bourgoignie; V M Buckalew; T Greene; A S Levey; N C Milas; L Paranandi; J C Peterson; J G Porush; S Rauch; J M Soucie; C Stollar
Journal:  Hypertension       Date:  1997-02       Impact factor: 10.190

4.  A study of the quality of life and cost-utility of renal transplantation.

Authors:  A Laupacis; P Keown; N Pus; H Krueger; B Ferguson; C Wong; N Muirhead
Journal:  Kidney Int       Date:  1996-07       Impact factor: 10.612

5.  Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study.

Authors:  L G Hunsicker; S Adler; A Caggiula; B K England; T Greene; J W Kusek; N L Rogers; P E Teschan
Journal:  Kidney Int       Date:  1997-06       Impact factor: 10.612

6.  Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.

Authors:  O Samuelsson; H Mulec; C Knight-Gibson; P O Attman; B Kron; R Larsson; L Weiss; H Wedel; P Alaupovic
Journal:  Nephrol Dial Transplant       Date:  1997-09       Impact factor: 5.992

7.  Awareness, treatment, and control of hypertension in Canada.

Authors:  M R Joffres; P Ghadirian; J G Fodor; A Petrasovits; A Chockalingam; P Hamet
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

Review 8.  The place of hypertension among the risk factors for renal function in chronic renal failure.

Authors:  L Oldrizzi; C Rugiu; V De Biase; G Maschio
Journal:  Am J Kidney Dis       Date:  1993-05       Impact factor: 8.860

9.  Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group.

Authors:  F Locatelli; D Marcelli; M Comelli; D Alberti; G Graziani; G Buccianti; B Redaelli; A Giangrande
Journal:  Nephrol Dial Transplant       Date:  1996-03       Impact factor: 5.992

10.  Cost analysis of dialysis treatments for end-stage renal disease (ESRD).

Authors:  R Goeree; J Manalich; P Grootendorst; M L Beecroft; D N Churchill
Journal:  Clin Invest Med       Date:  1995-12       Impact factor: 0.825

View more
  3 in total

Review 1.  Nephrology: 4. Strategies for the care of adults with chronic kidney disease.

Authors:  Caroline Stigant; Lesley Stevens; Adeera Levin
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

2.  Late referral for assessment of renal failure.

Authors:  Frank Kee; Elizabeth A Reaney; A Peter Maxwell; Damian G Fogarty; Gerard Savage; C Christopher Patterson
Journal:  J Epidemiol Community Health       Date:  2005-05       Impact factor: 3.710

3.  Assessment and modeling of routinely used biochemical laboratory data of healthy individuals and end-stage renal failure (ESRF) patients by three different chemometric methods.

Authors:  Agelos Papaioannou; George Rigas; Panagiotis Plageras; George A Karikas; George Karamanis
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.